BIOAGE LABS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
BIOAGE LABS, INC. (BIOA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.86 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-05
- BIOAGE LABS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 267.50K shares, a 107.16% increase year-over-year.
- BIOAGE LABS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 1.60M shares, a 42.24% decline year-over-year.
- BIOAGE LABS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 3.00K shares, a 98.03% decline year-over-year.
- BIOAGE LABS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 67.00K shares.
- BIOAGE LABS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 2.96M shares, a 6.45% decline from fiscal 2024.
- BIOAGE LABS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 3.17M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 267.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 1.86M shares 10-Q · filed 2026-08-05 | 1.87M shares derived: sum of 3 quarters · filed 2026-08-05 | 1.93M shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 1.60M shares 10-Q · filed 2026-05-08 | 1.60M shares derived: sum of 2 quarters · filed 2026-05-08 | 1.67M shares derived: sum of 3 quarters · filed 2026-05-08 | 1.80M shares derived: sum of 4 quarters · filed 2026-05-08 |
| 2025-12-31 | 3.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | 70.00K shares derived: sum of 2 quarters · filed 2026-03-24 | 199.13K shares derived: sum of 3 quarters · filed 2026-03-24 | 2.96M shares 10-K · filed 2026-03-24 |
| 2025-09-30 | 67.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 196.13K shares derived: sum of 2 quarters · filed 2025-11-06 | 2.96M shares 10-Q · filed 2025-11-06 | 3.11M shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 129.13K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 2.89M shares 10-Q · filed 2025-08-06 | 3.05M shares derived: sum of 3 quarters · filed 2025-08-06 | |
| 2025-03-31 | 2.77M shares 10-Q · filed 2025-05-06 | 2.92M shares derived: sum of 2 quarters · filed 2025-05-06 | ||
| 2024-12-31 | 152.40K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | 3.17M shares 10-K · filed 2025-03-20 | ||
| 2024-09-30 | 3.02M shares 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |